Filing Flows › Champions Oncology (CSBR) › Q1 FY26
Champions Oncology (CSBR) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Sep 15, 2025
Champions Oncology (CSBR) reported revenue of $14.0M for the first quarter fiscal 2026 (Q1 FY26), -0.5% from a year earlier and +13% from the quarter before. Operating margin was -3.8%, net loss $466K (3.3% of revenue).
Champions Oncology, Q1 FY26: revenue $14.0M (-0.5% year over year), operating margin -3.8%, net loss $466K, operating cash flow $600K. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.0M | +13% | -0.5% |
| Operating profit | −$527K | — | — |
| Net earnings | −$466K | — | — |
| Operating cash flow | $600K | -91% | +93% |
| Free cash flow | $554K | -92% | +78% |
What changed
Revenue was $14.0M in Q1 FY26, roughly flat year over year and up 13% from the previous quarter. Pharmacology services was the largest line at 95% of revenue. Other TOS revenue lost $538K year over year (down 54%), 815% of the total change.
Operating costs exceeded revenue by $527K, an operating margin of -3.8%. Total costs grew 14% against flat revenue. The fastest-growing cost line was Research & development (+43%). The quarter ended with a net loss of $466K, narrower than the previous quarter's $1.8M loss. Minority interests bore $30K of it: to shareholders the quarter was a loss of $436K.
Operating cash flow was $600K (up 93% year over year). Non-cash charges added back $358K of depreciation and amortization and $208K of share-based compensation. Working capital and other items added $500K. Capital expenditures of $46K left free cash flow of $554K.
Questions
What was Champions Oncology's revenue in the first quarter fiscal 2026?
Champions Oncology (CSBR) reported revenue of $14.0M for the first quarter fiscal 2026 (Q1 FY26), -0.5% from a year earlier and +13% from the quarter before.
Was Champions Oncology profitable in the first quarter fiscal 2026?
Operating loss was $527K (-3.8% of revenue) and net loss $466K.
Source: Champions Oncology 10-Q on SEC EDGAR.